drugset / Trial / NCT00370981

Exploratory Study of Pagoclone in Men With Premature Ejaculation.

NCT00370981 ↗

Phase 2 Completed 100 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

Timeline

Start
2006-07
Primary completion
2006-07
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pagoclone Small molecule 0.15 mg —
Subject Pagoclone Small molecule 0.3 mg —
Subject Pagoclone Small molecule 0.6 mg —

Indications